BioWorld

Nov. 19, 2003

View Archived Issues

Neose, Novo Enter Potential $55.6M Protein License Dea

Diabetic Mice Reveal Insulin In Spleen Cells, Pointing To Human Type I Cure In Pending Clinicals

Focused On Brain, CNS Disorders, Saegis Raises $30M In Its Series B

Phoenix Pharmacologics Starts Phase III Study In Liver Cancer

Keryx Has Cash For Three Years After $15M Private Placement

Vitex Halts Phase III Chronic Trial Of Inactine, Seeks New Financing

Other News To Note

Genome Therapeutics, Genesoft To Merge In $80M All-Stock Deal

Genome Therapeutics Inc. and Genesoft Pharmaceuticals Inc. said they have entered a definitive agreement for an all-stock merger that would leave the new entity with one antibiotic preparing to launch and another in Phase III trials. (BioWorld Today) Read More

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...